The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells

Mack, Kelly M.; Canada, Robert G.; Andrews, Paul A.

doi:10.1007/s002800050563

Cited by 9 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that the enhancement of cisplatin cytotoxicity by DPM in MDA/R cells employ a mechanism that does not involve an increase in the cellular accumulation of cisplatin. Mack et al 27 , have suggested that cisplatin resistance in MDA-MB-231 human breast cancer cells may in part be due to an increase in the detoxification of cisplatin via elevated levels of glutathione. The enhancement of DNA repair is a cellular response to cisplatin resistance and, to achieve higher levels of resistance, the cell induces mechanisms that affect drug accumulation and/or detoxification 28 .…”

Section: Discussionmentioning

confidence: 99%

Synergism between dipyridamole and cisplatin in human breast cancer cells in vitro

Perussi¹,

Paltoo²,

Toppin³

et al. 2003

Quím. Nova

View full text Add to dashboard Cite

Cisplatin is very effective in the treatment of metastatic breast cancer. However, the development of cellular resistance is a serious problem in cisplatin chemotherapy. In the present work, the effects of dipyridamole (DPM) on the cellular accumulation and cytotoxicity of cisplatin was studied in cisplatinsensitive (MDA/S) and cisplatinresistant (MDA/R) human breast cancer cells. In the presence of 30 µM DPM, the IC50 of cisplatin was reduced by 39% for both cell lines. Combination index analysis revealed that cisplatin and dipyridamole interact synergistically in MDA/R cells. In the MDA/S cells, the cellular accumulation of cisplatin increased by 57 ± 8% in the presence of 30 µM DPM. In the MDA/R cells, the cellular accumulation of cisplatin remained the same with or without 30 µM DPM. The results suggest that the enhancement of cisplatin cytotoxicity by DPM in MDA/S cells may be related to a DPM-induced increase in cisplatin accumulation, but the enhanced cytotoxicity in MDA/R cells employs a mechanism that does not involve an increase in the cellular accumulation of cisplatin

show abstract

Section: Discussionmentioning

confidence: 99%

Synergism between dipyridamole and cisplatin in human breast cancer cells in vitro

Perussi¹,

Paltoo²,

Toppin³

et al. 2003

Quím. Nova

View full text Add to dashboard Cite

show abstract

“…In addition, they are resistant to CDDP [26]. This has lead to their use as a model to study cisplatin resistance in general and, more specifically, cisplatin resistance in triple-negative breast cancers [27–29]. …”

Section: Introductionmentioning

confidence: 99%

Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance

Lingeman

Hickey

Malkas

2014

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Background An 8 amino acid peptide sequence derived from proliferating cell nuclear antigen (PCNA) has been shown to effectively kill several breast cancer and neuroblastoma cell lines when added exogenously to cell cultures. Methods In this study, the expression of the 8 amino acid peptide sequence (caPeptide) was placed under control of a tetracycline responsive promoter in MDA-MB-231 cells. Results Endogenous expression of the peptide resulted in an increase in genomic DNA damage. CaPeptide induction combined with treatment of sublethal doses of cisplatin resulted in a marked increase in death of the cisplatin-resistant MDA-MB-231 cell line. CaPeptide was found to interact with POLD3, one of the subunits of DNA polymerase delta necessary for binding to PCNA. Conclusion These results suggest an important line of inquiry into the possible role that caPeptide might play in the reversal of cisplatin resistance in breast and other cancers. This is of particular interest in those cancers where cisplatin is the first line of chemotherapy and where the acquisition of resistance is a common malady.

show abstract

“…These findings imply that the receptor binding of Tb 3+ can modulate the cytotoxic activity of cisplatin. It is notable that by the action of Tb 3+ , more cisplatin was accumulated in cisplatin-resistant MDA cells than in cisplatin-sensitive ones [58]. The defective accumulation of DDP has been shown to be a prominent feature in many DDP-resistant cell lines.…”

Section: Enhancement Of the Anticancer Activity Of Cisplatinmentioning

confidence: 99%

“…The defective accumulation of DDP has been shown to be a prominent feature in many DDP-resistant cell lines. In an effort to circumvent this problem, it was examined the cellular accumulation of DDP was determined in the presence of terbium (Tb 3+ ) [58]. The authors also examined the effects of verapamil on the cellular accumulation of DDP in order to delineate the specific interaction of Tb 3+ and DDP.…”

Section: Enhancement Of the Anticancer Activity Of Cisplatinmentioning

confidence: 99%

Lanthanides as Anticancer Agents

Kostova

2005

CMCACA

103

View full text Add to dashboard Cite

The application of inorganic chemistry to medicine is a rapidly developing field, and novel therapeutic and diagnostic metals and metal complexes are now having an impact on medical practice. Advances in biocoordination chemistry are crucial for improving the design of compounds to reduce toxic side effects and understand their mechanisms of action. A lot of metal-based drugs are widely used in the treatment of cancer. The clinical success of cisplatin and other platinum complexes is limited by significant side effects acquired or intrinsic resistance. Therefore, much attention has focused on designing new coordination compounds with improved pharmacological properties and a broader range of antitumor activity. Strategies for developing new anticancer agents include the incorporation of carrier groups that can target tumor cells with high specificity. Also of interest is to develop complexes that bind to DNA in a fundamentally different manner than cisplatin, in an attempt to overcome the resistance pathways that have evolved to eliminate the drug. This review focuses on recent advances in developing lanthanide anticancer agents with an emphasis on lanthanide coordination complexes. These complexes may provide a broader spectrum of antitumor activity. They were compared with classical platinum anticancer drugs. Lanthanides are also of interest because of their therapeutic radioisotopes. The dominant pharmacological applications of lanthanides are as agents in radioimmunotherapy and photodynamic therapy.

show abstract

The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells

Abstract: In agreement with earlier studies, the plasma membrane of MDA cell lines contain a specific Tb(3+)-binding protein. Our findings suggest that the Tb(3+)-binding protein may be intimately associated with the accumulation of DDP in breast tumor cells.

Cited by 9 publications

References 16 publications

Synergism between dipyridamole and cisplatin in human breast cancer cells in vitro

Synergism between dipyridamole and cisplatin in human breast cancer cells in vitro

Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance

Lanthanides as Anticancer Agents

Contact Info

Product

Resources

About